
World’s second largest API company to be created by Sanofi
pharmafile | February 25, 2020 | News story | Manufacturing and Production | API, APIs, China API, Coronavirus API, India API, Sanofi
Sanofi plans to create a new company in Europe dedicated to the production and marketing of active pharmaceutical ingredients (API).
This news comes amidst the coronavirus outbreak, which is threatening the global drug production line due to many countries importing APIs from China.
This new entity will help balance Europe’s reliance on these Chinese and Indian API imports. It would consist of Sanofi combining its European API production sites in Italy, Germany, the UK, Hungary and two others in France. When created, it would rank as the second largest API company in the world with a predicted $1 billion in sales by 2022. Sanofi would hold a 30% stake in the new company and intends it to be debt free to maximise its investment capacities.
Commenting on the plans, Philippe Luscan, Executive Vice President, Global Industrial Affairs at Sanofi, said: “Based on the expertise and experience built over decades within our industrial network, this new entity would help ensure a greater stability in supplying drugs to millions of patients in Europe and beyond. With this endeavour, this new entity would be agile as a standalone company, and able to unlock its growth potential, especially in capturing new third-party sales and all the opportunities of a market growing at a pace of 6% per year.”
Conor Kavanagh
Related Content

Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …

Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition
The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …

Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline
Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology …






